24.38
-0.67
(-2.67%)
At close: January 10 at 4:00:02 PM EST
24.40
+0.02
+(0.08%)
After hours: January 10 at 6:17:49 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 2 | 6 | 6 |
| Avg. Estimate | 0.94 | 0.68 | 2.58 | 3.11 |
| Low Estimate | 0.89 | 0.67 | 2.53 | 3.03 |
| High Estimate | 1.02 | 0.68 | 2.66 | 3.25 |
| Year Ago EPS | 0.86 | 0.29 | 2.58 | 2.58 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 3 | 5 | 5 |
| Avg. Estimate | 1.2B | 1.13B | 4.43B | 4.64B |
| Low Estimate | 1.18B | 1.12B | 4.41B | 4.55B |
| High Estimate | 1.21B | 1.15B | 4.45B | 4.7B |
| Year Ago Sales | 1.16B | 1.08B | 4.66B | 4.43B |
| Sales Growth (year/est) | 3.55% | 4.72% | -4.77% | 4.55% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.83 | 0.23 | 0.46 | 0.81 |
| EPS Actual | 0.86 | 0.29 | 0.53 | 0.81 |
| Difference | 0.03 | 0.06 | 0.07 | -0 |
| Surprise % | 3.59% | 24.29% | 16.04% | -0.24% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.94 | 0.68 | 2.58 | 3.11 |
| 7 Days Ago | 0.95 | 0.7 | 2.59 | 3.12 |
| 30 Days Ago | 0.95 | 0.7 | 2.59 | 3.12 |
| 60 Days Ago | 0.95 | 0.7 | 2.59 | 3.12 |
| 90 Days Ago | 0.91 | 0.72 | 2.57 | 3.14 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | -- | 4 | 1 |
| Up Last 30 Days | 4 | -- | 3 | 1 |
| Down Last 7 Days | 1 | 1 | -- | 4 |
| Down Last 30 Days | -- | 1 | 1 | 4 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| PRGO | 9.76% | 132.76% | 0.18% | 20.31% |
| S&P 500 | 8.59% | 11.42% | 13.98% | 13.43% |
Upgrades & Downgrades
| Downgrade | Piper Sandler: Overweight to Neutral | 1/6/2025 |
| Maintains | Canaccord Genuity: Buy to Buy | 9/30/2024 |
| Downgrade | Jefferies: Buy to Hold | 9/23/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 7/11/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 6/13/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 4/12/2024 |
Related Tickers
BHC Bausch Health Companies Inc.
7.88
+0.64%
VTRS Viatris Inc.
11.67
-2.42%
ELAN Elanco Animal Health Incorporated
11.43
-1.04%
ALKS Alkermes plc
28.08
-1.20%
ANIK Anika Therapeutics, Inc.
15.57
-2.32%
TEVA Teva Pharmaceutical Industries Limited
20.94
-2.56%
NBIX Neurocrine Biosciences, Inc.
140.90
+1.58%
HCM HUTCHMED (China) Limited
15.03
-1.31%
COLL Collegium Pharmaceutical, Inc.
32.91
-1.29%
LFCR Lifecore Biomedical, Inc.
6.29
+8.45%